- Home
- AMSF vs CDNA Comparison
AMSF vs CDNA Comparison
Compare AMSF & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- CDNA
- Stock Information
- Founded
- AMSF 1985
- CDNA 1998
- Country
- AMSF United States
- CDNA United States
- Employees
- AMSF N/A
- CDNA N/A
- Industry
- AMSF Accident &Health Insurance
- CDNA Medical Specialities
- Sector
- AMSF Finance
- CDNA Health Care
- Exchange
- AMSF Nasdaq
- CDNA Nasdaq
- Market Cap
- AMSF 857.2M
- CDNA 712.2M
- IPO Year
- AMSF 2005
- CDNA 2014
- Fundamental
- Price
- AMSF $41.16
- CDNA $15.10
- Analyst Decision
- AMSF Buy
- CDNA Buy
- Analyst Count
- AMSF 3
- CDNA 8
- Target Price
- AMSF $58.33
- CDNA $26.86
- AVG Volume (30 Days)
- AMSF 134.1K
- CDNA 1.2M
- Earning Date
- AMSF 10-29-2025
- CDNA 11-03-2025
- Dividend Yield
- AMSF 11.12%
- CDNA N/A
- EPS Growth
- AMSF N/A
- CDNA N/A
- EPS
- AMSF 2.63
- CDNA 1.00
- Revenue
- AMSF $306,470,000.00
- CDNA $340,826,000.00
- Revenue This Year
- AMSF $2.98
- CDNA $12.73
- Revenue Next Year
- AMSF $5.32
- CDNA $11.90
- P/E Ratio
- AMSF $15.59
- CDNA $14.45
- Revenue Growth
- AMSF N/A
- CDNA 14.72
- 52 Week Low
- AMSF $40.03
- CDNA $10.96
- 52 Week High
- AMSF $60.24
- CDNA $26.85
- Technical
- Relative Strength Index (RSI)
- AMSF 40.06
- CDNA 56.34
- Support Level
- AMSF $40.04
- CDNA $14.39
- Resistance Level
- AMSF $42.22
- CDNA $15.42
- Average True Range (ATR)
- AMSF 0.83
- CDNA 0.57
- MACD
- AMSF -0.06
- CDNA -0.05
- Stochastic Oscillator
- AMSF 31.39
- CDNA 74.19
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.